FCGR1A

Summary

FCGR1A (Fc gamma receptor Ia, HGNC:3613) is a protein-coding gene on chromosome 1q21.2, encoding High affinity immunoglobulin gamma Fc receptor I (P12314). High affinity receptor for the Fc region of immunoglobulins gamma. It is a selective cancer dependency (DepMap: 79.5% of cell lines).

This gene encodes a protein that plays an important role in the immune response. This protein is a high-affinity Fc-gamma receptor. The gene is one of three related gene family members located on chromosome 1.

Source: NCBI Gene 2209 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 50 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 79.5% of screened cell lines
• MANE Select transcript: NM_000566

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3613
Approved symbol	FCGR1A
Name	Fc gamma receptor Ia
Location	1q21.2
Locus type	gene with protein product
Status	Approved
Aliases	CD64, CD64A, FcgammaRI, FcgammaRIa, FCG1, FCGR1
Ensembl gene	ENSG00000150337
Ensembl biotype	protein_coding
OMIM	146760
Entrez	2209

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000369168, ENST00000444948, ENST00000489479, ENST00000489704, ENST00000866776, ENST00000866777, ENST00000866778, ENST00000964516

RefSeq mRNA: 9 — MANE Select: NM_000566 NM_000566, NM_001378804, NM_001378805, NM_001378806, NM_001378807, NM_001378808, NM_001378809, NM_001378810, NM_001378811

CCDS: CCDS933

Canonical transcript exons

ENST00000369168 — 6 exons

Exon	Start	End
ENSE00001300931	149790054	149790338
ENSE00001308813	149788366	149788617
ENSE00001448945	149791237	149791675
ENSE00001662479	149782694	149782774
ENSE00001693285	149784003	149784257
ENSE00001785655	149783170	149783190

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 97.34.

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	97.34	gold quality
leukocyte	CL:0000738	97.06	gold quality
granulocyte	CL:0000094	95.27	gold quality
blood	UBERON:0000178	94.62	gold quality
placenta	UBERON:0001987	94.56	gold quality
right coronary artery	UBERON:0001625	92.29	gold quality
vermiform appendix	UBERON:0001154	91.97	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	90.20	gold quality
substantia nigra	UBERON:0002038	87.71	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.30	gold quality
bone marrow	UBERON:0002371	85.65	gold quality
spleen	UBERON:0002106	85.21	gold quality
bone marrow cell	CL:0002092	84.86	gold quality
upper lobe of left lung	UBERON:0008952	84.79	gold quality
descending thoracic aorta	UBERON:0002345	84.62	gold quality
amygdala	UBERON:0001876	82.51	gold quality
temporal lobe	UBERON:0001871	82.48	gold quality
thoracic aorta	UBERON:0001515	82.38	gold quality
ascending aorta	UBERON:0001496	81.77	gold quality
Ammon’s horn	UBERON:0001954	81.74	gold quality
right lung	UBERON:0002167	81.70	gold quality
lung	UBERON:0002048	81.64	gold quality
corpus callosum	UBERON:0002336	81.38	gold quality
smooth muscle tissue	UBERON:0001135	81.01	gold quality
right adrenal gland	UBERON:0001233	80.98	gold quality
left adrenal gland	UBERON:0001234	80.83	gold quality
gall bladder	UBERON:0002110	80.82	gold quality
caudate nucleus	UBERON:0001873	80.42	gold quality
right adrenal gland cortex	UBERON:0035827	80.26	gold quality
putamen	UBERON:0001874	80.04	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-GEOD-149689	yes	397.81
E-MTAB-8498	yes	318.83
E-MTAB-6701	yes	50.70
E-MTAB-6678	yes	38.80
E-ANND-3	yes	14.53

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, GATA1, GLI3, HR, IRF6, NFKB1, NFKB, NR3C1, RELA, SPI1, STAT1, STAT3, STAT5A, STAT5B, TBP

miRNA regulators (miRDB)

64 targeting FCGR1A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-7978	99.86	66.90	856
HSA-MIR-130B-5P	99.83	68.50	1888
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-10393-5P	99.65	68.01	1368
HSA-MIR-4672	99.50	71.58	2893
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-653-5P	99.46	67.35	1300
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-130A-5P	99.33	70.26	2623
HSA-MIR-593-3P	99.22	67.28	1327
HSA-MIR-422A	99.18	65.83	550
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-6895-3P	98.79	65.69	996
HSA-MIR-7113-3P	98.75	65.71	1120

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 79.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• At least two alternate mechanisms of internalization of Fc gamma RI are influenced by the presence or absence of ligand and demonstrate the receptor’s physiologic potential to transport a large antigenic load into antigen presenting cells for processing. (PMID:11714794)
• Distinct functions for STAT1 and PU.1 in transcriptional activation of Fc gamma receptor I promoter. (PMID:12130529)
• CY domain alters gamma-chain tyrosine-based signaling and phagocytosis (PMID:12200451)
• Activation of mast cells through the high affinity IgG receptor. (PMID:12217397)
• cross-linking FcgammaRI and -II but not FcgammaRIII activates transcription factor NF-kappaB (PMID:12377934)
• FcgammaRI plays a major role in anti-HPA-1a-mediated platelet phagocytosis by monocytes while FcgammaRIIa, is of little or minor importance only. (PMID:12581186)
• specific sequences in the FcgammaRIIIA and FcgammaRI transmembrane domains govern their different interactions with the gamma chain in cell surface expression and phagocytosis (PMID:12756162)
• The levels of peripheral blood neutrophil CD(64) may help us distinguish infection from disease activation in systemic lupus erythematosus (SLE). (PMID:14728877)
• periplakin (PPL) as a selective interacting protein for the intracellular tail of FcgammaRI but no other activatory FcRs (PMID:15229321)
• FcgammaRIIa polymorphism is not an important genetic risk factor for chronic rejection of kidney allografts. (PMID:15251320)
• Fc fragments of IgG from healthy donors or purified monoclonal anti-human Fc gamma receptor (FcgammaR) antibody strengthen the participation of FcgammaRI (CD64) in HIV-1 inhibition on monocyte-derived macrophages. (PMID:15528366)
• analysis of C-reactive protein binding to FcgammaRI, FcgammaRIIa, and C1q (PMID:15878871)
• results imply a novel functional role of CD13 and Fc gamma receptors (CD32 and CD64)as members of a multimeric receptor complex (PMID:15883031)
• Thus, these results suggest that the lipid raft-associated 67LR plays an important role in mediating the FcepsilonRI-suppressive action of EGCG. (PMID:16140266)
• in human aortic endothelial cells, CRP upregulates monocyte-endothelial adhesion by activation of NF-kappaB through engaging the Fcgamma receptors CD32 and CD64 (PMID:16603696)
• findings showed that that both Fcgamma RIA and FcgammaRIIA mediated enhanced dengue virus immune complex infectivity but that FcgammaRIIA appeared to do so far more effectively (PMID:17005690)
• Fcgamma receptor I Ab and Fcgamma receptor I play an important role in the regulation of alopecia areata (AA), are useful for a marker of the disease prognosis and are worth intense research for the reasonable and specific therapy of AA. (PMID:17124586)
• finding documents the capacity of FcgammaRI to mediate potent antimalaria immunity (PMID:17511516)
• kinetics of neutrophil membrane CD64 expression were examined during a standardized inflammatory response, using a human endotoxemia model (PMID:17621550)
• In platelets, GPVI-FcRgamma has evolved to transmit sustained signals in order to maintain spreading over several hours, as well as facilitating rapid activation through release of feedback agonists and integrin activation. (PMID:17764536)
• FcgammaRI is hyperexpressed in the intestinal mast cells of Crohn disease patients. (PMID:17827066)
• An alternatively spliced 4.1G product is shown to be associated with increased Fc gamma RI binding in yeast two-hybrid assays, and to be selectively enriched in most immune cells at the transcript level. (PMID:18023480)
• the response to vascular injury provoked by human C-Reactive Protein in ovariectomized C-reactive protein transgenic mice depends on Fc gamma RI and probably requires its expression by F4/80+ cells (PMID:18063701)
• Activation of mast cells through aggregation of Fc-gamma receptor I leads to degranulation, induction of prosurvival gene bfl-1, and promotion of cell survival. (PMID:18071883)
• FcgammaRI predominantly resides in thin detergent-insoluble buoyant membranes, together with FcRgamma-chain, but independent of cross-linking ligand (PMID:18207250)
• RAGE could also behave as a receptor for Mycobacterium tuberculosis (PMID:18279703)
• Data show that in cardiac surgical patients the expression of activation marker FcgammaR1 (CD64) on monocytes is increased earlier in comparison with granulocytes in both “on-pump” and “off-pump” patients. (PMID:18320015)
• Data show that CD64 indexes for neutrophils and monocytes, and CD163 index for neutrophils can all be used for discrimination of SIRS and sepsis in critically ill neonates and children. (PMID:18604302)
• These results provide a mechanism by which Fcgamma receptors can elevate circulating BLyS levels and promote autoantibody production in immune complex-mediated autoimmune diseases. (PMID:18606652)
• lower numbers of CD64-positive circulating DCs during gestation than in adults (PMID:18798798)
• Splenic macrophages that take up opsonized platelets via FcgammaRI are major APCs for cryptic GPIIb/IIIa peptides, and are central to the maintenance of anti-platelet autoantibody production in ITP patients (PMID:18826388)
• Aspartic acid at position 265 of IgG is a residue critically implicated in triggering the Fc-associated effector functions of IgG, probably by defining a crucial three-dimensional structure of the Fc region. (PMID:18941257)
• Data suggest that flagellin-specific IgG/Fc gamma receptor I complex immune responses activate mast cells in the intestine and play important roles in the pathogenesis of intestinal immune inflammation. (PMID:18974296)
• expression of CD49d and CD64 on blood neutrophils is upregulated in plasma from patients with sepsis (PMID:19011162)
• circulating monocytes activated by immune complexes and/or proinflammatory mediators upregulate surface expression of FcgammaRI/CD64 in systemic lupus erythematosus (PMID:19144150)
• Structural characterization of a human Fc fragment engineered for extended serum half-life. (PMID:19250681)
• Activation of monocytes via Fc gamma RI induces differentiation, imparting specific inflammatory functions of autoreactive T cells that may contribute to pathogenesis of immune complex-mediated tissue injury. (PMID:19635920)
• Data show that LILRB4 is a potent inhibitor of monocyte activation via FcgammaRI. (PMID:19833736)
• HRG has the unique property of complexing with IgG and facilitating a proinflammatory innate immune response to promote the clearance of necrotic cells via FcgammaRI (PMID:20071662)
• Aglycosylated immunoglobulin G can be engineered to display unique FcgammaR selectivity profiles that, in turn, mediate antibody dependent cell cytotoxicity. (PMID:20080725)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Fcgr1	ENSMUSG00000015947
rattus_norvegicus	Fcgr1a	ENSRNOG00000021199

Paralogs (17): FCGR2B (ENSG00000072694), FCRLA (ENSG00000132185), FCRL2 (ENSG00000132704), FCGR2A (ENSG00000143226), FCRL5 (ENSG00000143297), FCRL3 (ENSG00000160856), FCRLB (ENSG00000162746), FCGR3B (ENSG00000162747), FCRL4 (ENSG00000163518), FCRL1 (ENSG00000163534), FCER1A (ENSG00000179639), FCRL6 (ENSG00000181036), C17orf99 (ENSG00000187997), FCGR3A (ENSG00000203747), FCGR2C (ENSG00000244682), PECAM1 (ENSG00000261371), MILR1 (ENSG00000271605)

Protein

Protein identifiers

High affinity immunoglobulin gamma Fc receptor I — P12314 (reviewed: P12314)

Alternative names: Fc-gamma RI, Fc-gamma RIA

All UniProt accessions (2): P12314, C9JSN8

UniProt curated annotations — full annotation on UniProt →

Function. High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses. Mediates IgG effector functions on monocytes triggering antibody-dependent cellular cytotoxicity (ADCC) of virus-infected cells.

Subunit / interactions. Interacts with the Fc region of IgG1, IgG2, IgG3 and IgG4 isotypes assembled in immune complexes. Interacts with FCERG1; forms a functional signaling complex. Interacts with FLNA; prevents FCGR1A degradation. Interacts with EPB41L2, LAT and PPL. Interacts with HCK and LYN.

Subcellular location. Cell membrane.

Tissue specificity. Monocyte/macrophage specific.

Post-translational modifications. Phosphorylated on serine residues.

Similarity. Belongs to the immunoglobulin superfamily. FCGR1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
P12314-1	1, A	yes
P12314-2	2, B

RefSeq proteins (9): NP_000557, NP_001365733, NP_001365734, NP_001365735, NP_001365736, NP_001365737, NP_001365738, NP_001365739, NP_001365740 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013151	Immunoglobulin_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050488	Ig_Fc_receptor	Family

Pfam: PF00047, PF13895, PF13927

UniProt features (67 total): strand 26, mutagenesis site 8, glycosylation site 7, sequence conflict 6, helix 4, disulfide bond 3, domain 3, topological domain 2, region of interest 2, signal peptide 1, chain 1, short sequence motif 1, splice variant 1, sequence variant 1, transmembrane region 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
4W4O	X-RAY DIFFRACTION	1.8
8DIR	X-RAY DIFFRACTION	2.3
8DJ7	X-RAY DIFFRACTION	2.39
4ZNE	X-RAY DIFFRACTION	2.42
8DIN	X-RAY DIFFRACTION	2.5
3RJD	X-RAY DIFFRACTION	2.65
4X4M	X-RAY DIFFRACTION	3.48

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P12314-F1	85.10	0.66

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 43–85, 124–168, 212–260

Glycosylation sites (7): 59, 78, 152, 159, 163, 195, 240

Mutagenesis-validated functional residues (8):

Position	Phenotype
173	2- to 5-fold reduction of binding affinity for igg1, igg3 and igg4.
173	3- to 10-fold reduction of binding affinity for igg1, igg3 and igg4.
174	2- to 5-fold reduction of binding affinity for igg1, igg3 and igg4.
174	15- to 30-fold reduction of binding affinity for igg1, igg3 and igg4.
175	20-fold reduction of binding affinity for igg1, igg3 and igg4.
175	3- to 10-fold reduction of binding affinity for igg1, igg3 and igg4.
306	decreases cell membrane expression by 50% in absence of fcer1g.
306	increases cell membrane expression in absence of fcer1g.

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-1236978	Cross-presentation of soluble exogenous antigens (endosomes)
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-2029481	FCGR activation
R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation
R-HSA-2029485	Role of phospholipids in phagocytosis
R-HSA-877300	Interferon gamma signaling
R-HSA-9664323	FCGR3A-mediated IL10 synthesis

MSigDB gene sets: 353 (showing top): REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_INFLAMMATORY_RESPONSE_TO_ANTIGENIC_STIMULUS, GOBP_POSITIVE_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_POSITIVE_REGULATION_OF_ENDOCYTOSIS, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, GOBP_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, MODULE_64, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOCC_CELL_SURFACE, MODULE_128, GOBP_LEUKOCYTE_MEDIATED_CYTOTOXICITY, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION

GO Biological Process (19): antibody-dependent cellular cytotoxicity (GO:0001788), positive regulation of type IIa hypersensitivity (GO:0001798), positive regulation of type III hypersensitivity (GO:0001805), receptor-mediated endocytosis (GO:0006898), phagocytosis, recognition (GO:0006910), phagocytosis, engulfment (GO:0006911), immune response (GO:0006955), signal transduction (GO:0007165), cell surface receptor signaling pathway (GO:0007166), positive regulation of tumor necrosis factor production (GO:0032760), Fc-gamma receptor signaling pathway (GO:0038094), antigen processing and presentation of exogenous peptide antigen via MHC class I (GO:0042590), defense response to bacterium (GO:0042742), innate immune response (GO:0045087), positive regulation of phagocytosis (GO:0050766), immune system process (GO:0002376), response to bacterium (GO:0009617), antigen processing and presentation of exogenous antigen (GO:0019884), regulation of immune response (GO:0050776)

GO Molecular Function (4): IgG receptor activity (GO:0019770), high-affinity IgG receptor activity (GO:0019771), IgG binding (GO:0019864), protein binding (GO:0005515)

GO Cellular Component (5): plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), clathrin-coated endocytic vesicle membrane (GO:0030669), early endosome membrane (GO:0031901), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Fcgamma receptor (FCGR) dependent phagocytosis	3
Antigen processing-Cross presentation	1
Adaptive Immune System	1
Interferon Signaling	1
Anti-inflammatory response favouring Leishmania parasite infection	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
phagocytosis	3
type IIa hypersensitivity	2
immune response	2
leukocyte mediated cytotoxicity	1
regulation of type IIa hypersensitivity	1
positive regulation of type II hypersensitivity	1
type III hypersensitivity	1
regulation of type III hypersensitivity	1
positive regulation of hypersensitivity	1
positive regulation of myeloid leukocyte mediated immunity	1
positive regulation of immunoglobulin mediated immune response	1
endocytosis	1
cell recognition	1
cargo receptor activity	1
plasma membrane invagination	1
immune system process	1
response to stimulus	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
signal transduction	1
tumor necrosis factor production	1
regulation of tumor necrosis factor production	1
positive regulation of tumor necrosis factor superfamily cytokine production	1
Fc receptor signaling pathway	1
antigen processing and presentation of peptide antigen via MHC class I	1
antigen processing and presentation of exogenous peptide antigen	1
defense response	1
response to bacterium	1
defense response to symbiont	1
positive regulation of endocytosis	1
regulation of phagocytosis	1
biological_process	1
response to other organism	1
antigen processing and presentation	1
regulation of immune system process	1
regulation of response to stimulus	1
immunoglobulin receptor activity	1

Protein interactions and networks

STRING

2812 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FCGR1A	IGF1	P01343	987
FCGR1A	FCER1G	P30273	970
FCGR1A	FCGR3A	P08637	959
FCGR1A	IGF2	P01344	937
FCGR1A	FCGRT	P55899	883
FCGR1A	CD4	P01730	881
FCGR1A	ERBB2	P04626	879
FCGR1A	FCGR2A	P12318	846
FCGR1A	FCAR	P24071	841
FCGR1A	ESR1	P03372	821
FCGR1A	CD19	P15391	820
FCGR1A	FCGR3B	O75015	818
FCGR1A	PIGR	P01833	816
FCGR1A	ANPEP	P15144	815
FCGR1A	ITGAM	P11215	813

IntAct

83 interactions, top by confidence:

A	B	Type	Score
IGHG1	FCGR1A	psi-mi:“MI:0407”(direct interaction)	0.560
FCGR1A	FCER1G	psi-mi:“MI:0407”(direct interaction)	0.560
FCGR1A	EPB41L2	psi-mi:“MI:0915”(physical association)	0.560
EPB41L2	FCGR1A	psi-mi:“MI:0915”(physical association)	0.560
EPB41L2	FCGR1A	psi-mi:“MI:0403”(colocalization)	0.560
BMP10	FCGR1A	psi-mi:“MI:0915”(physical association)	0.560
ADIPOQ	FCGR1A	psi-mi:“MI:0915”(physical association)	0.560
ASGR1	FCGR1A	psi-mi:“MI:0915”(physical association)	0.560
CLEC7A	FCGR1A	psi-mi:“MI:0915”(physical association)	0.560
CLDN19	FCGR1A	psi-mi:“MI:0915”(physical association)	0.560
VSTM1	FCGR1A	psi-mi:“MI:0915”(physical association)	0.560
UPK2	FCGR1A	psi-mi:“MI:0915”(physical association)	0.560
FCGR1A	JAGN1	psi-mi:“MI:0915”(physical association)	0.560
FCGR1A	CD163	psi-mi:“MI:0915”(physical association)	0.560
FCGR1A	TNMD	psi-mi:“MI:0915”(physical association)	0.560
FCGR1A	RPRM	psi-mi:“MI:0915”(physical association)	0.560
FCGR1A	NRSN1	psi-mi:“MI:0915”(physical association)	0.560
FCGR1A	MALL	psi-mi:“MI:0915”(physical association)	0.560
FCGR1A	ADIPOQ	psi-mi:“MI:0915”(physical association)	0.560
FCGR1A	CLEC7A	psi-mi:“MI:0915”(physical association)	0.560
FCGR1A	CLDN19	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (57): FCGR1A (Synthetic Lethality), FCGR1A (Co-localization), FCGR1A (Co-localization), ITIH2 (Affinity Capture-MS), HBA2 (Affinity Capture-MS), PCDH17 (Affinity Capture-MS), PCDH12 (Affinity Capture-MS), FREM2 (Affinity Capture-MS), PCDH7 (Affinity Capture-MS), CDC42BPA (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ACAD8 (Affinity Capture-MS), FRAS1 (Affinity Capture-MS), SNTB2 (Affinity Capture-MS), PCDH20 (Affinity Capture-MS)

ESM2 similar proteins: A0A0B4J1G0, A0A0G2KBC9, A3RFZ7, B6A8R8, E2RP87, G1T7E7, G1TR84, H0VDZ8, M3XWH1, O75015, P08101, P08508, P08637, P0DTI4, P12314, P12318, P12319, P12371, P13597, P13598, P20489, P26151, P27645, P31995, P35330, P50283, P51866, P79107, P82957, Q00238, Q08481, Q09TM2, Q09TM4, Q14952, Q28942, Q3B8P2, Q3SWT0, Q5NKV1, Q5NKV2, Q60513

Diamond homologs: A0A0B4J1G0, A3RFZ7, E2RP87, G1T7E7, G1TR84, H0VDZ8, M3XWH1, O75015, P08101, P08508, P08637, P0DTI4, P12314, P12318, P12319, P12371, P20489, P26151, P27645, P31994, P31995, P79107, Q09TM2, Q09TM4, Q28110, Q28942, Q3B8P2, Q5DRQ8, Q60513, Q63203, Q6BAA4, Q6XPU4, Q8SPV8, Q8SPW2, Q920A9, Q92637, Q96PJ5, Q96RD9, Q9N2I5, A1YIY0

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
“Immune complexes”	“up-regulates activity”	FCGR1A
FCGR1A	up-regulates	M2_polarization
SPI1	“up-regulates quantity by expression”	FCGR1A	“transcriptional regulation”
porfimer	“down-regulates activity”	FCGR1A	“chemical inhibition”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 38 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
cell adhesion	6	6.4×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	35
Likely benign	8
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

674 predictions. Top by Δscore:

Variant	Effect	Δscore
1:149782771:TGGGG:T	donor_loss	0.9900
1:149782772:GGG:G	donor_gain	0.9900
1:149782773:GG:G	donor_gain	0.9900
1:149782773:GGG:G	donor_gain	0.9900
1:149782773:GGGTA:G	donor_loss	0.9900
1:149782774:GG:G	donor_gain	0.9900
1:149782775:G:C	donor_loss	0.9900
1:149782775:G:GG	donor_gain	0.9900
1:149782776:T:A	donor_loss	0.9900
1:149783990:A:AG	acceptor_gain	0.9900
1:149790051:TAGAG:T	acceptor_gain	0.9800
1:149791235:A:AG	acceptor_gain	0.9800
1:149791236:G:GG	acceptor_gain	0.9800
1:149790052:A:AG	acceptor_gain	0.9700
1:149790052:AGAGC:A	acceptor_gain	0.9700
1:149790053:G:GG	acceptor_gain	0.9700
1:149791232:TTCA:T	acceptor_loss	0.9700
1:149791235:AGG:A	acceptor_loss	0.9700
1:149791236:G:GC	acceptor_loss	0.9700
1:149790053:GA:G	acceptor_gain	0.9600
1:149790053:GAGCT:G	acceptor_gain	0.9600
1:149791236:GGC:G	acceptor_gain	0.9500
1:149783998:A:G	acceptor_gain	0.9400
1:149791229:T:A	acceptor_gain	0.9400
1:149791235:AG:A	acceptor_gain	0.9400
1:149791236:GG:G	acceptor_gain	0.9400
1:149782770:TTGGG:T	donor_gain	0.9300
1:149783987:T:A	acceptor_gain	0.9300
1:149788443:GA:G	donor_gain	0.9300
1:149790050:TTAGA:T	acceptor_gain	0.9300

AlphaMissense

2427 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:149788428:T:A	C124S	0.993
1:149788429:G:C	C124S	0.993
1:149788560:T:A	C168S	0.992
1:149788561:G:C	C168S	0.992
1:149788428:T:C	C124R	0.986
1:149788560:T:C	C168R	0.983
1:149788562:C:G	C168W	0.983
1:149790272:T:A	C260S	0.981
1:149790273:G:C	C260S	0.981
1:149784118:G:C	W56C	0.978
1:149784118:G:T	W56C	0.978
1:149784203:T:A	C85S	0.978
1:149784204:G:C	C85S	0.978
1:149788561:G:A	C168Y	0.978
1:149788429:G:A	C124Y	0.977
1:149790128:T:A	C212S	0.977
1:149790129:G:C	C212S	0.977
1:149788430:T:G	C124W	0.974
1:149784197:T:G	Y83D	0.973
1:149784116:T:A	W56R	0.971
1:149784116:T:C	W56R	0.971
1:149790129:G:A	C212Y	0.971
1:149790311:A:C	S273R	0.971
1:149790313:C:A	S273R	0.971
1:149790313:C:G	S273R	0.971
1:149788554:T:G	Y166D	0.970
1:149790272:T:C	C260R	0.969
1:149788370:G:C	W104C	0.968
1:149788370:G:T	W104C	0.968
1:149784077:T:A	C43S	0.967

dbSNP variants (sampled 300 via entrez): RS1050191 (1:149784109 T>C), RS1050204 (1:149791362 G>A), RS1050208 (1:149791405 T>C), RS1050210 (1:149791520 G>A), RS1050211 (1:149791544 C>A,G,T), RS1050212 (1:149791635 G>A), RS10544446 (1:149789418 AATG>A,AATGATG), RS10670379 (1:149785408 GTTTTTTTTTTTTTT>G,GT,GTTT,GTTTTT,GTTTTTT,GTTTTTTT,GTTTTTTTTTTT,GTTTTTTTTTTTT,GTTTTTTTTTTTTT,GTTTTTTTTTTTTTTT,GTTTTTTTTTTTTTTTT,GTTTTTTTTTTTTTTTTT,GTTTTTTTTTTTTTTTTTT,GTTTTTTTTTTTTTTTTTTT,GTTTTTTTTTTTTTTTTTTTTTT), RS10736382 (1:149796976 T>G), RS10888462 (1:149796806 G>C), RS10888463 (1:149797398 T>A), RS10888464 (1:149800313 G>A), RS10888465 (1:149800489 C>T), RS111328914 (1:149789418 A>G), RS111648065 (1:149794772 A>G,T)

Disease associations

OMIM: gene MIM:146760 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5349 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.00	IC50	100	nM	CHEMBL2377172
5.54	IC50	2900	nM	CHEMBL570394

PubChem BioAssay actives

2 with measured affinity, of 27 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-methyl-5-[(5-methyl-2-phenylpyrazol-3-yl)disulfanyl]-1-phenylpyrazole	743962: Inhibition of FCgamma receptor in human PBMC assessed as inhibition of opsonized RBC phagocytosis incubated for 1 hr prior to RBC addition measured after 2 hrs by monocyte monolayer assay	ic50	0.1000	uM
2-[[4-(3-aminoanilino)-6-[2-[4-[[4-(3-aminoanilino)-6-[2-(4-aminophenyl)ethylamino]-1,3,5-triazin-2-yl]amino]phenyl]ethylamino]-1,3,5-triazin-2-yl]amino]ethanol	443579: Inhibition of heat aggregated human IgG binding to human Fc-gamma-R1	ic50	2.9000	uM

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	increases expression, decreases expression	3
Tretinoin	affects expression, increases expression	2
triphenyl phosphate	affects expression	1
maleic acid	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
tamibarotene	affects expression	1
di-n-butylphosphoric acid	affects expression	1
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	decreases expression, decreases reaction, increases reaction	1
licochalcone B	increases expression	1
Arsenic Trioxide	decreases expression, decreases reaction, increases expression	1
Acetaminophen	increases expression	1
Air Pollutants, Occupational	decreases expression	1
Allergens	decreases expression	1
Amphotericin B	increases expression	1
Vehicle Emissions	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Dust	decreases expression	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression, affects cotreatment	1
Ozone	increases expression	1
Paraquat	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	decreases methylation	1
Zidovudine	affects cotreatment, increases expression	1
Antirheumatic Agents	decreases expression	1
Sirolimus	decreases reaction, increases reaction, decreases expression	1
Particulate Matter	decreases expression	1

ChEMBL screening assays

15 unique, capped per target: 15 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1011029	Binding	Inhibition of IGFR1	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. — J Med Chem

Cellosaurus cell lines

5 cell lines: 4 cancer cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1E18	TZM-bl/FcgammaRI	Cancer cell line	Female
CVCL_B9XX	Abcam THP-1 FCGR1A KO	Cancer cell line	Male
CVCL_E5I7	CHO-K1/CD64	Spontaneously immortalized cell line	Female
CVCL_E8DU	BPS Bioscience THP-1 FCGR1A KO	Cancer cell line	Male
CVCL_JX96	NK-92MIhCD64	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.